Impact Factor
4.27
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
7.17
1,515 total citations
h5-index
43
h5 depth signal
Cited share
92.9%
210 of 226
Total citations
1,515
Citation footprint
Metric signal
6.61
External metric anchor
Self-citation
0.2%
3 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
596
China
107
Italy
74
United Kingdom
41
Canada
34
Citing Fields of Research
Oncology
365
Immunology
141
Musculoskeletal & Nerve Cancer
110
Breast Cancer
91
Lymphomas
83
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,724
Articles tracked across the journal lifetime
Indexed publication set
226
210 cited publications
Last 12 months
60
5.5 publications/month
Open access share
43.3%
26 OA publications in the last year
Leading citing country
United States
596 citing publications
Leading citing field
Oncology
365 citing publications
Latest tracked publication
6 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Apr. 2000-
v1n1, Apr. 2000-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Musculoskeletal & Nerve Cancer
Breast Cancer
Immunology
Lymphomas
Lung Cancer
Broad Categories
Neoplasms
Musculoskeletal & Nerve Cancer
Prostate Cancer
Immunology
Liver & Colon Cancer
Hematology
Cancer Drugs
Breast Cancer
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s11864-026-01415-y
Open DOI
Personalized Therapy with Mercaptopurine in Acute Lymphoblastic Leukemia: Current Advances and Challenges
02
DOI 10.1007/s11864-026-01414-z
Open DOI
Systemic Options for Recurrent Abdominal Low-grade Well-differentiated Liposarcoma
03
DOI 10.1007/s11864-026-01413-0
Open DOI
Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma
04
DOI 10.1007/s11864-026-01411-2
Open DOI
Antibody-Drug Conjugates in the Treatment of Esophageal Cancer
05
DOI 10.1007/s11864-026-01412-1
Open DOI
Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment
06
DOI 10.1007/s11864-026-01409-w
Open DOI
Current Treatment Options Guided by Molecular Classification in Endometrial Cancer
Opinion Statement In our view, molecular classification should guide, but not independently determine, treatment for endometrial cancer. The four major molecular subtypes—POLE-mutated (POLEmut), mismatch repair-deficient/microsatellite i...
07
DOI 10.1007/s11864-026-01410-3
Open DOI
Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach
Opinion statement Microscopically positive surgical margins (R1) complicate 15–30% of soft tissue sarcoma (STS) resections and independently worsen local recurrence and overall survival, yet no randomised trial has targeted the R1 popula...
08
09
DOI 10.1007/s11864-026-01407-y
Open DOI
Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives
10
DOI 10.1007/s11864-026-01406-z
Open DOI
Current Treatment Options and Emerging Technologies for Pelvic Bone Tumors: From Limb Salvage to Precision Oncology
Bibliographical & Catalog Notes
Description based on: Vol. 2, no. 2 (Apr. 2001); title from cover.
Print issues ceased with v. 11 (2010).
Also issued online.